Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of Lenvatinib in combination with Pembrolizumab and Nivolumab in patients with advanced intrahepatic cholagiocarcinoma

Next Previous
X
Search
Trial Profile

A study of Lenvatinib in combination with Pembrolizumab and Nivolumab in patients with advanced intrahepatic cholagiocarcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Feb 2018 New trial record
    • 20 Jan 2018 Results from preliminary data assessing correlation between therapeutic response and high tumor mutational burden from 450 gene next generation sequencing presented at the 2018 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top